Across TCGA pan-cancer cohorts, MAN1A2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAN1A2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MAN1A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAN1A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and SKCM are the cancer types where MAN1A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.150	0.557	.007	9	view →
UCEC	DFS	Median	All	0.921	0.620	.028	8	view →
SKCM	OS	Median	All	0.081	0.392	.012	2	view →
COAD	OS	Median	All	0.461	0.873	.008	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MAN1A2 tumor-vs-normal RNA expression · all MAN1A2 data types